Paris-based venture capital firm Newfund has successfully secured €60 million for its initial specialized fund aimed squarely at European companies developing brain technologies. This dedicated capital seeks to support founders working on everything from neuro-pharmaceutical research to enhanced patient care pathways, addressing what the firm sees as an embryonic but rapidly expanding sector.

Partner Anne-Sophie Saint-Martin asserts the timing is right, citing maturity where science meets technological capability, especially with AI tools unlocking deeper insights from complex neurological data. The fund plans to deploy $1m-3m checks into roughly 25 seed-stage European startups across neurology and psychiatry, marking a shift from Newfund’s prior generalist offerings.

Global investment figures show US startups captured 85% of the €4.2 billion raised in 2025, prompting Newfund’s focus on bridging that gap for European innovators. A core condition of investment involves US market expansion, specifically aiming for FDA approval and establishing an initial patient community, given active M&A activity in US healthtech.

Eight of the nine companies already backed by this new vehicle are commercializing within the US market, demonstrating the firm’s commitment to transatlantic scale for its portfolio companies.